Otilimab

Unassigned

New Medicines

Moderate to severe rheumatoid arthritis (RA), unresponsive to methotrexate

Information

New molecular entry
GlaxoSmithKline
GlaxoSmithKline

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein that mediates immune mediated diseases, including RA

One study in the UK found the population minimum prevalence of RA to be 1.16% in women and 0.44% in men. The incidence of the condition is low, with around 1.5 men and 3.6 women developing RA per 10,000 people per year [3].

Moderate to severe rheumatoid arthritis (RA), unresponsive to methotrexate
Subcutaneous injection

Trial or other data